NASDAQ : SVRA
Savara Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 4.82 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.22B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.22B |
| Enterprise Value | 1.08B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 205.46M |
| Shares Outstanding | 254.14M |
| Shares Change (YoY) | +12.05% |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | 2.10% |
| Owned by Institutions (%) | 59.02% |
| Float | 129.75M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 55.31 |
| PB Ratio | 8.52 |
| P/TBV Ratio | 9.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 10.13 |
| Quick Ratio | 9.99 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -105.48% |
| Return on Assets (ROA) | -50.15% |
| Return on Invested Capital (ROIC) | -55.03% |
| Return on Capital Employed (ROCE) | -81.80% |
| Weighted Average Cost of Capital (WACC) | 5.21% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.99M |
| Employee Count | 70 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.20 |
| 52-Week Price Change | +11.06% |
| 50-Day Moving Average | 5.08 |
| 200-Day Moving Average | 5.39 |
| Relative Strength Index (RSI) | 49.32 |
| Average Volume (20 Days) | 2,437,784 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 28.74M |
| Short Previous Month | 43.56M |
| Short % of Shares Out | 11.31% |
| Short % of Float | 22.15% |
| Short Ratio (days to cover) | 11.92 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -86.84M |
| Operating Income | -142.78M |
| Pretax Income | -139.31M |
| Net Income | -139.31M |
| EBITDA | -142.70M |
| EBIT | -142.78M |
| Earnings Per Share (EPS) | -$0.58 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 174.82M |
| Total Debt | 30.41M |
| Net Cash | 144.41M |
| Net Cash Per Share | $0.57 |
| Equity (Book Value) | 143.66M |
| Book Value Per Share | 0.57 |
| Working Capital | 160.72M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -110.38M |
| Capital Expenditures | -280,000 |
| Depreciation & Amortization | 76,000 |
| Net Borrowing | 1,000 |
| Free Cash Flow | -110.66M |
| FCF Per Share | -$0.44 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -12.05% |
| Shareholder Yield | -12.05% |
| Earnings Yield | -11.99% |
| FCF Yield | -9.03% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $11.06 |
| Price Target Difference | 129.46% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |